These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23610100)

  • 1. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial.
    Locatelli F; Dimkovic N; Spasovski G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1874-88. PubMed ID: 23610100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
    Hertel J; Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Nephron; 2015; 130(4):229-38. PubMed ID: 26184491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C; Dellanna F; Pontoriero G
    Nephrol Dial Transplant; 2014 May; 29(5):1061-73. PubMed ID: 24302608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients.
    Wanner C; März W; Varushchanka A; Apanasovich N; Dosta N; Yakubtsevich R; Locatelli F
    Clin Nephrol; 2014 Sep; 82(3):163-72. PubMed ID: 25079861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study.
    Locatelli F; Dimkovic N; Pontoriero G; Spasovski G; Pljesa S; Kostic S; Manning A; Sano H; Nakajima S
    Nephrol Dial Transplant; 2010 Feb; 25(2):574-81. PubMed ID: 19736246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.
    Locatelli F; Dimkovic N; Spasovski G
    Expert Opin Pharmacother; 2014 Jul; 15(10):1475-88. PubMed ID: 24914480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of colestilan on serum phosphorus in dialysis patients: A meta-analysis of the literature.
    Zhang Q; Li M; Chen J
    Nephrology (Carlton); 2016 Mar; 21(3):229-35. PubMed ID: 26272343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial.
    Kurihara S; Tsuruta Y; Akizawa T
    Nephrol Dial Transplant; 2005 Feb; 20(2):424-30. PubMed ID: 15673691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Blood Purif; 2016; 41(4):247-53. PubMed ID: 26670307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease.
    Sampson M; Faria N; Powell JJ;
    Nephrol Dial Transplant; 2021 Jul; 36(8):1399-1407. PubMed ID: 32651955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
    Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
    Akizawa T; Origasa H; Kameoka C; Tsukada J; Kuroishi K; Yamaguchi Y
    Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
    Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study.
    Kondo K; Kadowaki T
    Diabetes Obes Metab; 2010 Mar; 12(3):246-51. PubMed ID: 20047620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
    Maccubbin D; Tipping D; Kuznetsova O; Hanlon WA; Bostom AG
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):582-9. PubMed ID: 20299362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.